Clinical TrialJul 7, 2026, 07:01 AM
Aclarion Adds Texas Spine Care Center to CLARITY Trial
AI Summary
Aclarion, Inc. announced that Texas Spine Care Center has joined its CLARITY (Chronic Low Back Pain Randomized Independent Trial Study) trial as a new clinical site. The CLARITY study aims to demonstrate the clinical and economic value of Aclarion's Nociscan solution in spine surgery, which helps physicians identify the location of chronic low back pain. Texas Spine Care Center's focus on precise pain source identification aligns with Nociscan's capabilities, which has shown a 97% surgical success rate when Nociscan-positive discs are treated. The company anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
Key Highlights
- Texas Spine Care Center joins Aclarion's CLARITY trial as a new clinical site.
- The CLARITY trial is a 300-patient, prospective, randomized, multi-center study.
- Primary endpoint is change in back pain (100mm VAS Back) at 12 months.
- Nociscan has demonstrated a 97% surgical success rate when positive discs are treated.
- Initial internal data readout and public disclosure of early interim results are expected in Q4 2026.
- Texas Spine Care Center is a high-volume orthopedic spine practice.
- Nociscan uses MR Spectroscopy (MRS) and Augmented Intelligence (AI) to identify pain sources.
Price Impact
More from ACON